![Peter G. Linde](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter G. Linde
Corporate Officer/Principal bij
Walden Biosciences, Inc.
Profiel
Peter G.
Linde is currently the Chief Medical Officer at Walden Biosciences, Inc. He previously worked as the Senior Director-Clinical Development at FibroGen, Inc. and as the Vice President-Medical Research at Acceleron Pharma, Inc. From 2020 to 2021, he served as the Chief Medical Officer at Morphic Holding, Inc. Linde received his undergraduate degree from the Massachusetts Institute of Technology.
Actieve functies van Peter G. Linde
| Bedrijven | Functie | Begin |
|---|---|---|
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Corporate Officer/Principal | 11-10-2022 |
Eerdere bekende functies van Peter G. Linde
| Bedrijven | Functie | Einde |
|---|---|---|
| MORC HOLD | Hoofd Techniek/Wetenschap/O&O | 31-12-2021 |
| KYNTRA BIO, INC. | Corporate Officer/Principal | - |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Opleiding van Peter G. Linde
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
1
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
FibroGen, Inc.
 FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Health Services |
